Spyne, an AI-powered visual merchandising platform for the automotive industry, has raised $16 million in a Series A funding ...

Existing investors Accel, Storm Ventures, and Alteria Capital also participated in the funding round of the ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

This investment will fuel Spyne’s growth trajectory, focusing on aggressive expansion in the US and developing its ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

Spyne will also use the fresh capital to strengthen its go-to-market strategy, especially in the US market, where it plans to ...

Eli Lilly should easily beat the market again in 2025, as it did in 2024. Summit Therapeutics awaits a potentially huge ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

In a Series A fundraising round headed by Vertex Ventures, Spyne, an AI-powered visual marketing platform for the automobile ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

This investment will fuel Spyne's growth trajectory, focusing on aggressive expansion in the US and developing its ...